RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032
Overview
The RoE Pharmacogenetics Testing in Psychiatry-Depression Market is expected to reach a 18.33 USD Billion by 2032 and is projected to grow at a CAGR of 6.11% from 2025 to 2032.
Revenue, 2024 (USD Billion)
12.82
Forecast, 2032 (USD Billion)
18.33
CAGR, 2024 - 2032
6.11%
Report Coverage
RoE
RoE Pharmacogenetics Testing in Psychiatry-Depression Market 2018-2032 USD Billion
RoE Pharmacogenetics Testing in Psychiatry-Depression Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 12.82 USD Billion
- Projected Market Size (2032): 18.33 USD Billion
- CAGR (2025-2032): 6.11%
Key Findings of RoE Pharmacogenetics Testing in Psychiatry-Depression Market
- The RoE Pharmacogenetics Testing in Psychiatry-Depression Market was valued at 12.82 USD Billion in 2024.
- The RoE Pharmacogenetics Testing in Psychiatry-Depression Market is likely to grow at a CAGR of 6.11% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Whole Genome Sequencing in Test Segment accounted for the largest share of the market with a revenue of 13.39 USD Billion
- The fastest growing segment CYP2C19 in Gene Segment grew Fastest with a CAGR of 9.96% during the forecast period from 2024 to 2032.
RoE Pharmacogenetics Testing in Psychiatry-Depression Market Scope
RoE Pharmacogenetics Testing in Psychiatry-Depression Market Segmentation & Scope
Type
- Psychotic Disorders
- Eating Disorders
- Bipolar Disorders
- Mood Disorders
- Depression
- Anxiety
Test
- Chromosomal Array Based Tests
- Whole Genome Sequencing
Product
- Software and Services
- Instruments
- Consumables
Gene
- COMT
- MTHFR
- SLC6A4
- Others
- CYP3A4
- HLA-A
- HTR2A/C
- HLA-B
- CYP2D6
- CYP2C9 AND VKORC1
- CYP2C19
Patient
- Child
- Geriatric
- Adult
End User
- Others
- Hospital and Clinics
- Diagnostics Laboratories
- Academic And Research Institutes
Distribution Channel
- Others
- Hospital Pharmacy
- Third Party Distribution
- Direct Tender
RoE Pharmacogenetics Testing in Psychiatry-Depression Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2022 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 12.82 USD Billion |
| Market Value in 2032 | 18.33 USD Billion |
| CAGR (2025-2032) | 6.11% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Type,Test,Product, Gene,Patient,End User,Distribution Channel |
Regional Insights:
-
Leading Market (2024-2032): RoE, leading in terms of revenue 12.82 USD Billion in 2024
- Key Country: RoE, leading in terms of revenue with value of 12.82 USD Billion in 2024.
Segments and Scope
-
RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Type
- Anxiety is the largest segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 4.47 USD Billion in the year 2024.
- Anxiety is the Fastest growing segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 8.68 % in forecast period 2025-2032.
-
RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Test
- Whole Genome Sequencing is the largest segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 13.39 USD Billion in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 9.20 % in forecast period 2025-2032.
-
RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Product
- Consumables is the largest segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 6.61 USD Billion in the year 2024.
- Consumables is the Fastest growing segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 8.11 % in forecast period 2025-2032.
-
RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Gene
- CYP2C19 is the largest segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 2.97 USD Billion in the year 2024.
- CYP2C19 is the Fastest growing segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 9.96 % in forecast period 2025-2032.
-
RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Patient
- Adult is the largest segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 6.66 USD Billion in the year 2024.
- Adult is the Fastest growing segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 7.66 % in forecast period 2025-2032.
-
RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By End User
- Hospital and Clinics is the largest segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 6.18 USD Billion in the year 2024.
- Hospital and Clinics is the Fastest growing segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 7.59 % in forecast period 2025-2032.
-
RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 6.40 USD Billion in the year 2024.
- Direct Tender is the Fastest growing segment in RoE Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 6.88 % in forecast period 2025-2032.
RoE Pharmacogenetics Testing in Psychiatry-Depression Market Company Share Analysis
| Company Name |
|
||
| Myriad Genetics, Inc. | |||
| Illumina, Inc. | |||
| Thermo Fisher Scientific Inc. | |||
| Qiagen | |||
| Sonic Healthcare Limited | |||
RoE Pharmacogenetics Testing in Psychiatry-Depression Market Geographical Sales Distribution, 2018-2032 USD Billion
RoE Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The RoE Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Type,Test,Product, Gene,Patient,End User,Distribution Channel.
RoE Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 12.82(Revenue in USD Billion) in 2022.
RoE Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 6.11% during the forecast period of 2024 to 2032.
The Whole Genome Sequencing segment is expected to dominate the RoE Pharmacogenetics Testing in Psychiatry-Depression Market, holding a largest market share of 13.39 USD Billion in 2024
Coming Soon....
RoE Pharmacogenetics Testing in Psychiatry-Depression Market Scope
RoE Pharmacogenetics Testing in Psychiatry-Depression Market Segmentation & Scope
Type
- Psychotic Disorders
- Eating Disorders
- Bipolar Disorders
- Mood Disorders
- Depression
- Anxiety
Test
- Chromosomal Array Based Tests
- Whole Genome Sequencing
Product
- Software and Services
- Instruments
- Consumables
Gene
- COMT
- MTHFR
- SLC6A4
- Others
- CYP3A4
- HLA-A
- HTR2A/C
- HLA-B
- CYP2D6
- CYP2C9 AND VKORC1
- CYP2C19
Patient
- Child
- Geriatric
- Adult
End User
- Others
- Hospital and Clinics
- Diagnostics Laboratories
- Academic And Research Institutes
Distribution Channel
- Others
- Hospital Pharmacy
- Third Party Distribution
- Direct Tender
Frequently Asked Questions
The RoE Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Type,Test,Product, Gene,Patient,End User,Distribution Channel.
RoE Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 12.82(Revenue in USD Billion) in 2022.
RoE Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 6.11% during the forecast period of 2024 to 2032.
The estimated market value of the RoE Pharmacogenetics Testing in Psychiatry-Depression Market for final year is USD 18.33 (USD Billion).
RoE Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling
Frequently Asked Questions
The RoE Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Type,Test,Product, Gene,Patient,End User,Distribution Channel.
RoE Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 12.82(Revenue in USD Billion) in 2022.
RoE Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 6.11% during the forecast period of 2024 to 2032.
The estimated market value of the RoE Pharmacogenetics Testing in Psychiatry-Depression Market for final year is USD 18.33 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.